(Q73364768)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Issues Regarding the Use of Heparin Following Streptokinase Therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1 reference

White HD

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Yusuf S

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 January 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thrombosis and Thrombolysis

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

5-10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf01063155

3 November 2019

exact match

0 references

cites work

Coronary angioscopy in patients with unstable angina pectoris

1 reference

12 December 2020

Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis

1 reference

12 December 2020

GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico

1 reference

12 December 2020

Influence of skinfold thickness on heparin absorption

1 reference

12 December 2020

Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase

1 reference

12 December 2020

Heparin kinetics in venous thrombosis and pulmonary embolism

1 reference

12 December 2020

Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma

1 reference

12 December 2020

The mode of action of heparin in plasma

1 reference

12 December 2020

Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction

1 reference

12 December 2020

Increased thrombin activity during thrombolysis

1 reference

12 December 2020

Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction

1 reference

12 December 2020

Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood

1 reference

12 December 2020

Activation/inactivation of human factor V by plasmin

1 reference

12 December 2020

In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group

1 reference

12 December 2020

Biochemical mechanisms of platelet activation

1 reference

12 December 2020

Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis

1 reference

12 December 2020

Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group

1 reference

12 December 2020

Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction

1 reference

12 December 2020

Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina

1 reference

12 December 2020

Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis

1 reference

12 December 2020

Role of heparin in coronary thrombolysis

1 reference

12 December 2020

Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)

1 reference

12 December 2020

Heparin doses and major bleedings

1 reference

12 December 2020

Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo

1 reference

12 December 2020

A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators

1 reference

12 December 2020

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

12 December 2020

Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage

1 reference

12 December 2020

Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).

1 reference

12 December 2020

Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial

1 reference

12 December 2020

Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy

1 reference

12 December 2020

Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator

1 reference

12 December 2020

Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency

1 reference

12 December 2020

Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. The SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group

1 reference

12 December 2020

McNicol GP,+MACNICOL GP, Douglas AS: Effect of fibrinogen degradation products on platelet aggregation

1 reference

12 December 2020

Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator

1 reference

12 December 2020

Suppression by heparin of smooth muscle cell proliferation in injured arteries

1 reference

12 December 2020

Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction

1 reference

12 December 2020

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

1 reference

12 December 2020

ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct S

1 reference

12 December 2020

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials

1 reference

12 December 2020

Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity

1 reference

12 December 2020

Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart

1 reference

12 December 2020

Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4.

1 reference

12 December 2020

Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin

1 reference

12 December 2020

Aspirin, heparin, or both to treat acute unstable angina

1 reference

12 December 2020

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

12 December 2020

Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin

1 reference

12 December 2020

Partial resistance to anticoagulation after streptokinase treatment for acute myocardial infarction

1 reference

12 December 2020

Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: an angioscopic study

1 reference

12 December 2020

Nonsurgical reperfusion in evolving myocardial infarction

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01063155

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10639209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference